[go: up one dir, main page]

MX2009009786A - Inhibidores de la via de hedgehog. - Google Patents

Inhibidores de la via de hedgehog.

Info

Publication number
MX2009009786A
MX2009009786A MX2009009786A MX2009009786A MX2009009786A MX 2009009786 A MX2009009786 A MX 2009009786A MX 2009009786 A MX2009009786 A MX 2009009786A MX 2009009786 A MX2009009786 A MX 2009009786A MX 2009009786 A MX2009009786 A MX 2009009786A
Authority
MX
Mexico
Prior art keywords
compound
inhibitors
hedgehog pathway
formula
methods
Prior art date
Application number
MX2009009786A
Other languages
English (en)
Inventor
Yong Wang
Charles K Marlowe
James W Leahy
Brian Hugh Ridgway
Morrison B Mac
William Bajjalieh
Zerom Tesfai
Grace Mann
Jeff Chen
Sergey Epshteyn
Timothy Patrick Forsyth
Tai Phat Huynh
Byung Gyu Kim
Matthew Sangyup Lee
Gary L Lewis
Xian Shi
Suleyman Bahceci
Joan C Sanglang
Craig Stacy Takeuchi
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of MX2009009786A publication Critical patent/MX2009009786A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a un compuesto de la Fórmula I (ver fórmula (I)) o un isómero individual de los mismos, donde el compuesto está opcionalmente en forma de sal aceptable para uso farmacéutico, hidrato, solvato o una combinación de los mismos, además de métodos para la preparación de un compuesto de la Fórmula 1 y métodos para usar un compuesto de la Fórmula I para el tratamiento del cáncer.
MX2009009786A 2007-03-14 2008-03-13 Inhibidores de la via de hedgehog. MX2009009786A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91816007P 2007-03-14 2007-03-14
US96261707P 2007-07-30 2007-07-30
PCT/US2008/056883 WO2008112913A1 (en) 2007-03-14 2008-03-13 Inhibitors of the hedgehog pathway

Publications (1)

Publication Number Publication Date
MX2009009786A true MX2009009786A (es) 2009-09-24

Family

ID=39760053

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009009786A MX2009009786A (es) 2007-03-14 2008-03-13 Inhibidores de la via de hedgehog.

Country Status (18)

Country Link
US (3) US8222263B2 (es)
EP (2) EP2134695A4 (es)
JP (1) JP5577104B2 (es)
KR (1) KR20090130051A (es)
CN (1) CN101679308B (es)
AR (1) AR065767A1 (es)
AU (1) AU2008224941C1 (es)
BR (1) BRPI0808772A2 (es)
CA (1) CA2680796A1 (es)
CO (1) CO6231031A2 (es)
EA (1) EA018441B1 (es)
GE (1) GEP20135925B (es)
IL (1) IL200603A (es)
MX (1) MX2009009786A (es)
NZ (2) NZ579480A (es)
SG (1) SG179418A1 (es)
TW (1) TWI430798B (es)
WO (1) WO2008112913A1 (es)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2074122T3 (pl) * 2006-09-15 2011-10-31 Pfizer Prod Inc Związki pirydo(2,3-D)pirymidynonowe i ich zastosowanie jako inhibitory PI3
TWI433674B (zh) 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類
CN101679308B (zh) 2007-03-14 2014-05-07 埃克塞里艾克西斯公司 Hedgehog途径抑制剂
US20100144756A1 (en) * 2007-07-13 2010-06-10 Bolea Christelle Novel heteroaromatic derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors
US8716479B2 (en) 2007-12-27 2014-05-06 Infinity Pharmaceuticals, Inc. Methods for stereoselective reduction
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
KR101569949B1 (ko) * 2008-02-26 2015-11-18 다케다 야쿠힌 고교 가부시키가이샤 융합 헤테로시클릭 유도체 및 이의 용도
WO2010028192A1 (en) 2008-09-03 2010-03-11 Repligen Corporation Compositions including 6-aminohexanoic acid derivatives as hdac inhibitors
US9345699B2 (en) 2009-06-09 2016-05-24 Nantbioscience, Inc. Isoquinoline, quinoline, and quinazoline derivatives as inhibitors of hedgehog signaling
EP2440058A4 (en) 2009-06-12 2012-11-21 Dana Farber Cancer Inst Inc MELTED HETEROCYCLIC COMPOUNDS AND APPLICATIONS THEREOF
CN102574791A (zh) 2009-08-05 2012-07-11 无限药品股份有限公司 环杷明类似物的酶促转氨基反应
BR112012004149A2 (pt) * 2009-08-25 2016-03-22 Abraxis Bioscience Llc terapia de combinação com composições de nanopartículas de taxano e inibidores de hedgehog
EP2937345B1 (en) 2009-12-29 2018-03-21 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
EP2571357B1 (en) 2010-05-21 2016-07-06 Infinity Pharmaceuticals, Inc. Chemical compounds, compositions and methods for kinase modulation
WO2011156321A1 (en) * 2010-06-07 2011-12-15 Novomedix, Llc Furanyl compounds and the use thereof
ES2581840T3 (es) * 2010-09-01 2016-09-07 Ambit Biosciences Corporation Pirazolilaminoquinazolina ópticamente activa y composiciones farmacéuticas y métodos de uso de la misma
WO2012037217A1 (en) 2010-09-14 2012-03-22 Infinity Pharmaceuticals, Inc. Transfer hydrogenation of cyclopamine analogs
CN103298474B (zh) 2010-11-10 2016-06-29 无限药品股份有限公司 杂环化合物及其用途
MX347708B (es) 2011-01-10 2017-05-09 Infinity Pharmaceuticals Inc Proceso para preparar isoquinolinonas y formas solidas de isoquinolinonas.
US9540395B2 (en) 2011-02-28 2017-01-10 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US10059723B2 (en) 2011-02-28 2018-08-28 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US8957066B2 (en) 2011-02-28 2015-02-17 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
CN103946226A (zh) 2011-07-19 2014-07-23 无限药品股份有限公司 杂环化合物及其应用
AU2012284088B2 (en) 2011-07-19 2015-10-08 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
DK2748166T3 (en) 2011-08-23 2018-10-29 Asana Biosciences Llc PYRIMIDO-PYRIDAZINON COMPOUNDS AND USE THEREOF
HK1199725A1 (en) 2011-08-29 2015-07-17 无限药品股份有限公司 Heterocyclic compounds and uses thereof
US20140309184A1 (en) * 2011-09-21 2014-10-16 University Of South Alabama Methods and compositions for the treatment of ovarian cancer
WO2013049332A1 (en) 2011-09-29 2013-04-04 Infinity Pharmaceuticals, Inc. Inhibitors of monoacylglycerol lipase and methods of their use
EP3569598A1 (en) 2011-11-17 2019-11-20 Dana Farber Cancer Institute, Inc. Inhibitors of c-jun-n-terminal kinase (jnk)
CA3132120C (en) 2012-02-08 2023-10-24 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP2909194A1 (en) 2012-10-18 2015-08-26 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
WO2014063054A1 (en) 2012-10-19 2014-04-24 Dana-Farber Cancer Institute, Inc. Bone marrow on x chromosome kinase (bmx) inhibitors and uses thereof
USRE48175E1 (en) 2012-10-19 2020-08-25 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
RU2702908C2 (ru) 2012-11-01 2019-10-14 Инфинити Фармасьютикалз, Инк. Лечение злокачественных опухолей с использованием модуляторов изоформ pi3-киназы
JP6293770B2 (ja) * 2012-11-05 2018-03-14 ナント ホールディングス アイピー，エルエルシー ヘッジホッグシグナル伝達経路阻害剤としての環状スルホンアミド含有誘導体
US9844541B2 (en) 2012-11-29 2017-12-19 Strasspharma, Llc Methods of modulating follicle stimulating hormone activity
CN103040824B (zh) * 2013-01-17 2015-05-27 四川大学 信号通路抑制剂及其制备方法和用途
CA2900652C (en) 2013-02-15 2021-05-04 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
KR102277833B1 (ko) 2013-02-20 2021-07-14 칼라 파마슈티컬스, 인크. 치료 화합물 및 그의 용도
NZ629037A (en) 2013-03-15 2017-04-28 Infinity Pharmaceuticals Inc Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
ES2680224T3 (es) 2013-03-15 2018-09-05 Biomarin Pharmaceutical Inc. Inhibidores de HDAC
US9192609B2 (en) 2013-04-17 2015-11-24 Hedgepath Pharmaceuticals, Inc. Treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors
CN104177363B (zh) * 2013-05-24 2018-06-05 江苏先声药业有限公司 双环杂环胺类Hedgehog信号通路抑制剂
RU2019134551A (ru) 2013-05-30 2019-11-22 Инфинити Фармасьютикалз, Инк. Лечение злокачественных опухолей с использованием модуляторов изоформ pi3-киназы
HUE057734T2 (hu) 2013-10-04 2022-06-28 Infinity Pharmaceuticals Inc Heterociklusos vegyületek és alkalmazásuk
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2015058140A1 (en) 2013-10-18 2015-04-23 Dana-Farber Cancer Institute, Inc. Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7)
ES2676734T3 (es) 2013-10-18 2018-07-24 Syros Pharmaceuticals, Inc. Compuestos heteroatómicos útiles para el tratamiento de enfermedades proliferativas
US20160244452A1 (en) 2013-10-21 2016-08-25 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN106061261B (zh) 2013-11-01 2018-04-24 卡拉制药公司 治疗化合物的结晶形式及其用途
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
CN113616656B (zh) 2014-03-19 2023-02-17 无限药品股份有限公司 用于治疗PI3K-γ介导的障碍的杂环化合物
SG11201607973XA (en) 2014-03-24 2016-11-29 Guangdong Zhongsheng Pharmaceutical Co Ltd Quinoline derivatives as smo inhibitors
US20150320754A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
WO2015164604A1 (en) 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged janus kinase inhibitors and uses thereof
WO2015164614A1 (en) 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Janus kinase inhibitors and uses thereof
WO2015168079A1 (en) 2014-04-29 2015-11-05 Infinity Pharmaceuticals, Inc. Pyrimidine or pyridine derivatives useful as pi3k inhibitors
CN104230853B (zh) * 2014-08-18 2016-04-13 湖南华腾制药有限公司 一种(对甲苯基)甲胺-n-乙基吗啉盐酸盐的制备方法
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
AU2015371251B2 (en) 2014-12-23 2020-06-11 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
JP2018507212A (ja) * 2015-02-20 2018-03-15 バイエル・ファルマ・アクティエンゲゼルシャフト Ｎ−フェニル−（モルホリン−４−イルまたはピペラジニル）アセトアミド誘導体およびｗｎｔシグナル伝達経路の阻害剤としてのその使用
CN107427521B (zh) 2015-03-27 2021-08-03 达纳-法伯癌症研究所股份有限公司 细胞周期蛋白依赖性激酶的抑制剂
US10369147B2 (en) 2015-06-04 2019-08-06 PellePharm, Inc. Topical formulations for delivery of hedgehog inhibitor compounds and use thereof
US10464897B2 (en) * 2015-06-05 2019-11-05 Dana-Farber Cancer Institute, Inc. Compounds and methods for treating cancer
US10702527B2 (en) 2015-06-12 2020-07-07 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
CA2996978A1 (en) 2015-09-09 2017-03-16 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
EP3350183B1 (en) 2015-09-14 2025-04-02 Twelve Therapeutics, Inc. Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
US20170231968A1 (en) 2016-02-11 2017-08-17 PellePharm, Inc. Method for relief of and treatment of pruritus
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
MX391135B (es) 2016-06-24 2025-03-21 Infinity Pharmaceuticals Inc Terapias de combinacion.
EP3509422A4 (en) 2016-09-08 2020-05-20 Kala Pharmaceuticals, Inc. CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF
WO2018048750A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
JP2019533641A (ja) 2016-09-08 2019-11-21 カラ ファーマシューティカルズ インコーポレイテッド 治療用化合物の結晶形態およびその使用
CN110139692B (zh) 2016-11-22 2023-08-25 财团法人生物技术开发中心 用于调节刺猬途径的杂芳基胺化合物和其制法和用途
CN118105392A (zh) 2017-04-28 2024-05-31 自由生物有限公司 治疗特应性皮炎以及提高活性药物成分稳定性的制剂、方法、试剂盒和剂型
CN107082765A (zh) * 2017-06-07 2017-08-22 常州大学 一种2‑氯‑4‑苯基喹唑啉的合成方法
IL318939A (en) * 2017-09-07 2025-04-01 Univ Res Inst Inc Augusta Specific AKT3 activator and its uses
IL274601B2 (en) * 2017-11-15 2024-04-01 Mirati Therapeutics Inc Kras g12c inhibitors
JP7590185B2 (ja) 2018-06-25 2024-11-26 ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド Ｔａｉｒｅファミリーキナーゼインヒビターおよびそれらの使用
AU2019413694B2 (en) 2018-12-28 2025-03-20 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 and uses thereof
CN115998742A (zh) * 2021-10-21 2023-04-25 澳门大学 一种bms-833923及其衍生物的应用及药物
CN116621722A (zh) * 2023-07-14 2023-08-22 甘肃帝邦升防水材料科技有限公司 超耐候柔性tpo自粘防水卷材及其制备方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US6004979A (en) * 1991-02-07 1999-12-21 Hoechst Marion Roussel Nitrogenous bicycles
MX9200299A (es) * 1991-02-07 1992-12-01 Roussel Uclaf Nuevos derivados biciclicos nitrogenados, su procedimiento de preparacion los nuevos compuestos intermedios obtenidos su aplicacion como medicamentos y las composiciones farmaceuticas que los contienen.
NZ325248A (en) * 1995-12-23 1999-09-29 Pfizer Res & Dev Quinoline and quinazoline compounds useful in therapy
US7235551B2 (en) * 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
US6849634B2 (en) 2000-12-21 2005-02-01 Icagen Potassium channel inhibitors
US7105667B2 (en) * 2001-05-01 2006-09-12 Bristol-Myers Squibb Co. Fused heterocyclic compounds and use thereof
PE20030008A1 (es) * 2001-06-19 2003-01-22 Bristol Myers Squibb Co Inhibidores duales de pde 7 y pde 4
JP2005500294A (ja) * 2001-06-19 2005-01-06 ブリストル−マイヤーズ　スクイブ　カンパニー ホスホジエステラーゼ７に対するピリミジン阻害剤
AU2004225977B2 (en) 2003-03-25 2011-03-24 Vertex Pharmaceuticals Incorporated Thiazoles useful as inhibitors of protein kinases
EP1610793A2 (en) 2003-03-25 2006-01-04 Vertex Pharmaceuticals Incorporated Thiazoles useful as inhibitors of protein kinases
ES2290743T3 (es) * 2003-04-30 2008-02-16 The Institutes For Pharmaceutical Discovery, Llc Heteroarilos sustituidos como inhibidores de las proteina-tirosina fosfatasas.
WO2005028467A1 (en) 2003-09-15 2005-03-31 Anadys Pharmaceuticals, Inc. Antibacterial 3,5-diaminopiperidine-substitute aromatic and heteroaromatic compounds
WO2005033288A2 (en) * 2003-09-29 2005-04-14 The Johns Hopkins University Hedgehog pathway antagonists
US7524862B2 (en) * 2004-04-14 2009-04-28 Boehringer Ingelheim International Gmbh Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds
ES2389955T3 (es) * 2004-04-30 2012-11-05 Genentech, Inc. Inhibidores de quinoxalina de la vía de señalización hedgehog
CA2579002C (en) * 2004-09-02 2012-11-27 Genentech, Inc. Pyridyl inhibitors of hedgehog signalling
GT200500321A (es) 2004-11-09 2006-09-04 Compuestos y composiciones como inhibidores de proteina kinase.
EP1879881A2 (en) * 2005-04-14 2008-01-23 Bristol-Myers Squibb Company Inhibitors of 11-beta hydroxysteroid dehydrogenase type i
WO2006128129A2 (en) 2005-05-26 2006-11-30 Synta Pharmaceuticals Corp. Method for treating cancer
US20070032493A1 (en) 2005-05-26 2007-02-08 Synta Pharmaceuticals Corp. Method for treating B cell regulated autoimmune disorders
JPWO2006126718A1 (ja) 2005-05-27 2008-12-25 田辺三菱製薬株式会社 ピラゾロピリミジン誘導体
US7855194B2 (en) * 2006-03-27 2010-12-21 Hoffmann-La Roche Inc. Pyrimidine, quinazoline, pteridine and triazine derivatives
US7851468B2 (en) * 2006-05-15 2010-12-14 Cephalon, Inc. Substituted pyrazolo[3,4-d]pyrimidines
US20100144755A1 (en) * 2006-06-16 2010-06-10 Glaxo Group Limited Novel Compounds
US20090318424A1 (en) * 2006-06-16 2009-12-24 Mauro Corsi Novel compounds
CN101679308B (zh) 2007-03-14 2014-05-07 埃克塞里艾克西斯公司 Hedgehog途径抑制剂

Also Published As

Publication number Publication date
TW200843777A (en) 2008-11-16
CA2680796A1 (en) 2008-09-18
TWI430798B (zh) 2014-03-21
JP2010521487A (ja) 2010-06-24
US20120245139A1 (en) 2012-09-27
WO2008112913A1 (en) 2008-09-18
CN101679308A (zh) 2010-03-24
SG179418A1 (en) 2012-04-27
IL200603A0 (en) 2010-05-17
EP2134695A1 (en) 2009-12-23
EA018441B1 (ru) 2013-08-30
EA200970856A1 (ru) 2010-04-30
JP5577104B2 (ja) 2014-08-20
US8796294B2 (en) 2014-08-05
NZ598251A (en) 2013-06-28
CO6231031A2 (es) 2010-12-20
US20120238570A1 (en) 2012-09-20
AU2008224941C1 (en) 2013-06-27
US8754092B2 (en) 2014-06-17
BRPI0808772A2 (pt) 2014-08-12
KR20090130051A (ko) 2009-12-17
US8222263B2 (en) 2012-07-17
US20090105211A1 (en) 2009-04-23
AR065767A1 (es) 2009-07-01
NZ579480A (en) 2012-03-30
IL200603A (en) 2014-08-31
CN101679308B (zh) 2014-05-07
EP2527330A1 (en) 2012-11-28
AU2008224941A1 (en) 2008-09-18
AU2008224941B2 (en) 2012-12-20
EP2134695A4 (en) 2011-05-25
GEP20135925B (en) 2013-10-10

Similar Documents

Publication Publication Date Title
MX2009009786A (es) Inhibidores de la via de hedgehog.
UA98141C2 (ru) Способы лечения с применением хинаксолиновых ингибиторов pi3k-альфа
TN2009000400A1 (en) Methods of treating cancer using pyridopyrimidininone inhibitors of pi3k alpha
PT1940839E (pt) Inibidores de piridopirimidinona pi3k alfa
MY146111A (en) Acylaminopyrazoles as fgfr inhibitors
MX2011009796A (es) Inhibidores de la cinasa pi3.
JO2886B1 (en) Useful compounds in the inhibition of CHK1
PH12012502057A1 (en) Compounds for inhibiting mitotic progression
TW200740776A (en) N-phenylbenzotriazolyl c-kit inhibitors
TW200738725A (en) Unsaturated mTOR inhibitors
MX2011011335A (es) Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamifero de rapamicina.
EA201390085A1 (ru) Композиции ингибиторов киназ для лечения рака
WO2009016460A8 (en) Pyrazole compounds and their use as raf inhibitors
JO2848B1 (en) Organic compounds
WO2009155121A3 (en) Inhibitors of pi3 kinase
PT2421879E (pt) Novos 7-deazapurina nucleósidos para utilizações terapêuticas
MY149512A (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
MX2010008460A (es) Derivado de tiazol y su uso como inhibidor de proteina-1 de adhesion vascular.
MY150747A (en) Pyrido[2,3-d] pyrimidin-7-one compounds as inhibitors of pi3k-alpha for the treatment of cancer
WO2010121675A3 (en) Thiazolyl-benzimidazoles
UA96969C2 (en) Acylaminopyrazoles as fgfr inhibitors
IN2012DN02816A (es)
WO2010014798A3 (en) Pyrimidotriazinediones and pyrimidopyrimidinediones and methods of using the same
UA99612C2 (en) Inhibitors of the hedgehog pathway
UA105525C2 (uk) Інгібітори pi3-кінази і/або mtor

Legal Events

Date Code Title Description
HH Correction or change in general
FG Grant or registration